2208
A liver biopsy in 2012 revealed marked fibrosis, leading the patient to start hepatitis C treatment with peginterferon alfa-2a, ribavirin and boceprevir.
 ( potential therapeutic event: treatment ,  fibrosis, leading the patient: Subject, peginterferon alfa-2a, ribavirin and boceprevir: Treatment, fibrosis: Treatment.Disorder, peginterferon alfa-2a: Treatment.Drug, ribavirin: Treatment.Drug, boceprevir: Treatment.Drug, ribavirin: Combination.Drug, boceprevir: Combination.Drug, peginterferon alfa-2a: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: treatment ,  fibrosis, leading the patient: Subject, peginterferon alfa-2a, ribavirin and boceprevir: Treatment, fibrosis: Treatment.Disorder, peginterferon alfa-2a: Treatment.Drug, ribavirin: Treatment.Drug, boceprevir: Treatment.Drug, ribavirin: Combination.Drug, boceprevir: Combination.Drug, peginterferon alfa-2a: Combination.Drug) 